Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia

Clinical trial NCT03851081 · WITHDRAWN

Trial details

NCT number: NCT03851081
Sponsor: Roswell Park Cancer Institute
Status: WITHDRAWN
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Allogeneic Hematopoietic Stem Cell Transplantation Recipient Blasts 5 Percent or More of Bone Marrow Nucleated Cells Blasts 5 Percent or More of Peripheral Blood White Cells CD22 Positive Lymphoblasts 20 Percent or More of Bone Marrow Nucleated Cells Lymphoblasts 20 Percent or More of Peripheral Blood White Cells Recurrent B Acute Lymphoblastic Leukemia Refractory B Acute Lymphoblastic Leukemia

Start date: 2021-01-21
Primary completion: 2023-01-21
Enrollment: 0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.